Efficacy and safety of trametinib use in pediatric brain tumors in a low- to middle-income country
Child's Nervous System · 2026
DOI: 10.1007/s00381-026-07464-w ↗Kurz gefasst
Fachartikel in der Zeitschrift Child's Nervous System, 2026. Verfasst von Roula Farah und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics and Pediatric Hematology/Oncology, LAU Medical Center Rizk Hospital, Beirut, Lebanon. dr.roulafarah@gmail.com. Hauptthemen laut MEDLINE: Pyrimidinones, Pyridones, Brain Neoplasms, Antineoplastic Agents. Die Arbeit nennt 19 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: Trametinib, a mitogen-activated protein kinase (MEK) inhibitor, is a promising targeted therapy for children with progressive, unresectable low-grade gliomas (LGGs) who have failed standard chemotherapy regimens. There are limited data on the use of targeted therapy in Low-Middle-Income Countries (LMIC), and specifically, there are no published data from Lebanon on the use, efficacy, and safety of these agents. METHODS: A retrospective review of the medical records of pediatric patients with brain tumors who received trametinib at the LAU Medical Center Rizk Hospital was undertaken, along with a detailed data collection and a family interview to evaluate the quality of life of the patients while administering this agent. RESULTS: Four pediatric patients diagnosed with progressive LGGs, harboring distinct molecular drivers (KIAA1549-BRAF, NF1 Loss, and BRAF V600E), were identified. Age range at diagnosis was 11 months to 10 years. Trametinib was obtained on a compassionate basis through an international Managed Access Program. The median duration of trametinib use was 30.2 months (range 22 to 35.5 months). Clinical improvement was observed in all patients along with partial radiographic response in one patient. The most common side effects were skin reactions and gastrointestinal complaints, with few therapy interruptions required. Quality-of-life assessment using the Pediatric Quality of Life Inventory™ 4.0 Generic Core Scales revealed significant heterogeneity, with physical and school function being the most affected. CONCLUSION: Despite few manageable side effects, the favorable outcomes on tumor response and quality of life of trametinib-based therapy in Lebanese pediatric LGG patients suggest that MEK inhibitors may be a feasible option in selected LMIC settings, when appropriate diagnostic and monitoring infrastructure is available.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics and Pediatric Hematology/Oncology, LAU Medical Center Rizk Hospital, Beirut, Lebanon. dr.roulafarah@gmail.com.
- LAU Gilbert and Rose-Marie Chagoury School of Medicine, Blat, Lebanon.
- Department of Pediatrics and Pediatric Hematology/Oncology, LAU Medical Center Rizk Hospital, Beirut, Lebanon.
- Division of Hematology/Oncology, The Hospital for Sick Children, Toronto, Ontario, Canada.
Zitieren
APA
Farah, R., Farah, R., Charro, E., Bedran, J., Daccache, R., & Bouffet, E. (2026). Efficacy and safety of trametinib use in pediatric brain tumors in a low- to middle-income country. Child's Nervous System. https://doi.org/10.1007/s00381-026-07464-w
Vancouver
Farah R, Farah R, Charro E, Bedran J, Daccache R, Bouffet E. Efficacy and safety of trametinib use in pediatric brain tumors in a low- to middle-income country. Child's Nervous System. 2026. doi:10.1007/s00381-026-07464-w
BibTeX
@article{Farah2026,
author = {Farah, Roula and Farah, Robin and Charro, Elie and Bedran, Joe and Daccache, Romy and Bouffet, Eric},
title = {Efficacy and safety of trametinib use in pediatric brain tumors in a low- to middle-income country},
journal = {Child's Nervous System},
year = {2026},
doi = {10.1007/s00381-026-07464-w}
}
EUVIMED